02270nas a2200265   4500000000100000008004100001260001700042100001900059700001200078700001500090700001800105700001900123700001500142700001400157700001400171700001600185700001500201700001500216245013900231250001500370300001100385490000700396520155500403020004601958       2012                            d  c-358526175641 aArima Hisatomi1 aOmae T.1 aTzourio C.1 aWoodward Mark1 aAnderson Craig1 aBousser M.1 aMancia G.1 aRodgers A1 aChalmers J.1 aNeal Bruce1 aMacmahon S00aEffects of blood pressure lowering on intracranial and extracranial bleeding in patients on antithrombotic therapy: the PROGRESS trial  a2012/04/27  a1675-70 v433 a<p>
BACKGROUND AND PURPOSE: Observational studies demonstrate strong associations between blood pressure and bleeding complications of antithrombotic therapy. The objective was to determine whether blood pressure lowering reduces risks of bleeding in patients on antithrombotic therapy. METHODS: This is a subsidiary analysis of the Perindopril Protection Against Recurrent Stroke Study (PROGRESS) trial, a randomized, placebo-controlled trial. A total of 6105 patients with cerebrovascular disease were randomly assigned to either active treatment (perindopril +/- indapamide) or placebo(s). The outcomes were intracranial and extracranial bleeding. RESULTS: There were 4876 (80%) patients on antithrombotic therapy at baseline. Over a mean follow-up of 3.9 years, 119 intracranial and 123 extracranial bleeding events were observed. Among patients with and without antithrombotic therapy, active treatment lowered blood pressure by 8.9/4.0 and 9.3/3.8 mm Hg and reduced the risks of intracranial bleeding by 46% (95% CI, 7%-69%) and 70% (39%-85%), respectively. However, active treatment did not reduce the risks of extracranial bleeding significantly in either group. Among patients on antithrombotic therapy, the lowest risk of intracranial bleeding was observed in participants with the lowest follow-up systolic blood pressure levels (median, 113 mm Hg). CONCLUSIONS: Blood pressure lowering provides protection against intracranial bleeding among patients with cerebrovascular disease including those receiving antithrombotic therapy.
</p>
  a1524-4628 (Electronic)0039-2499 (Linking)